Meet our leadership team – who between them – have a deep knowledge of and long track records in the biotech and pharmaceutical industries.
Geoff is a market leader in commercialising oncology diagnostics and brings 20 years’ experience in pharmaceuticals. He has successfully grown companies, built and led sales and business development teams, and been involved in developing many new potential cancer drugs.
Geoff is a successful business leader and is passionate about delivering value to patients, clients and shareholders.
Jonathan is a successful entrepreneur with a proven ability to develop, scale and sell companies in the medical field. He leads the board and is a present and integral member of the leadership team. After the successful growth and sale of Clinphone.
Jonathan co-founded and invested in Imagen, with the ambition of working with Gareth to develop an in vitro system that could help oncologists select the right treatments for their patients.
Gareth co-founded Imagen following senior scientific roles in AstraZeneca, with the vision of developing an accurate method of modelling cancer tumour in the lab. He is an innovator in his field having developed and patented various assay development methods and is a respected expert in cell biology.
Gareth is passionate about translating science into outcomes for patients and is responsible for leading the scientific strategy and implementation at Imagen.
Chris has a unique background of scientific and business experience being awarded a PhD in Cell Biology from the University of Manchester before developing and leading successful customer-centric sales teams in the pharmacology CRO sector.
Chris is passionate about improving the therapeutic options available for cancer patients and enabling the scientists that carry out this important work to achieve their goals.
Dominic has over 30 years’ experience in molecular and cellular biology with roles at the European Molecular Biology Laboratory, University of Geneva and Cancer Research UK. He has successfully led drug discovery projects for CRUK from target identification through to licencing. Dominic is an enthusiastic and highly skilled scientist who was recently elected as a Fellow to the Royal Society of Biology.
Steve is a highly experienced Chairman with an extensive track record of successful exits in the pharmaceutical space. He was the CFO and later CEO at Clinphone (working alongside Jonathan and Neil).
As CEO he led the business through IPO and subsequent sale to Parexel (a large US CRO). He was Chairman of CRF Health and Kinapse through their buyouts and successful exits. He is currently Chairman of Phlex Global, 4Ways and Pharmaspectra.
Richard Goldstein graduated from the University of Cambridge with a degree in Law in 1983. Following a period of practice as an M&A lawyer at a leading law firm, and then as Legal Counsel at Superdrug Stores PLC, he obtained an MBA with Distinction from INSEAD in France in 1990, before leading the buy-in, and subsequently the management, of Harding Brothers Limited, now the second-largest operator of retail environments on board luxury cruise ships. Richard now operates and manages the investment activities of a family investment office, and sits on the Board of a number of companies in which he is also involved as an investor, including Imagen.
Together with Jonathan, Neil founded Clinphone. The business went through private equity funding via Montagu/Hg to grow the business and successfully exit via float in 2006.
Neil is medically qualified and is a serial pharma entrepreneur, most recently he exited Cmed Group and Exco In Touch.
He is currently NED at Greenphire, a global clinical trial payment technology business.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
